Altimmune, Inc. (ALT): Price and Financial Metrics


Altimmune, Inc. (ALT): $4.85

-0.17 (-3.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALT POWR Grades


  • ALT scores best on the Sentiment dimension, with a Sentiment rank ahead of 54.17% of US stocks.
  • The strongest trend for ALT is in Growth, which has been heading down over the past 179 days.
  • ALT's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

ALT Stock Summary

  • The ratio of debt to operating expenses for Altimmune Inc is higher than it is for about merely 0.5% of US stocks.
  • ALT's price/sales ratio is 62.04; that's higher than the P/S ratio of 96.66% of US stocks.
  • Revenue growth over the past 12 months for Altimmune Inc comes in at -46.12%, a number that bests only 3.52% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Altimmune Inc, a group of peers worth examining would be ARAV, AGTC, SYBX, VBLT, and VTGN.
  • Visit ALT's SEC page to see the company's official filings. To visit the company's web site, go to altimmune.com.

ALT Valuation Summary

  • In comparison to the median Healthcare stock, ALT's price/earnings ratio is 123.84% lower, now standing at -8.7.
  • ALT's price/sales ratio has moved NA NA over the prior 194 months.
  • ALT's price/sales ratio has moved NA NA over the prior 194 months.

Below are key valuation metrics over time for ALT.

Stock Date P/S P/B P/E EV/EBIT
ALT 2021-08-31 95.6 2.5 -8.7 -6.1
ALT 2021-08-30 89.9 2.3 -8.2 -5.6
ALT 2021-08-27 93.7 2.4 -8.6 -6.0
ALT 2021-08-26 91.1 2.3 -8.3 -5.7
ALT 2021-08-25 88.0 2.3 -8.0 -5.4
ALT 2021-08-24 84.6 2.2 -7.7 -5.1

ALT Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at 29.03%.
  • The 3 year net cashflow from operations growth rate now stands at -327.56%.
  • Its 4 year cash and equivalents growth rate is now at -20.56%.
ALT's revenue has moved down $6,185,423 over the prior 34 months.

The table below shows ALT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 4.410356 -78.23794 -97.09082
2021-09-30 3.445404 -69.68439 -83.82328
2021-06-30 6.225836 -61.41412 -68.08273
2021-03-31 6.809849 -49.65839 -60.02294
2020-12-31 8.185027 -34.43664 -49.04448
2020-09-30 6.448122 -23.02531 -42.51933

ALT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALT has a Quality Grade of D, ranking ahead of 13.22% of graded US stocks.
  • ALT's asset turnover comes in at 0.025 -- ranking 360th of 682 Pharmaceutical Products stocks.
  • OPTN, ENTA, and ELTP are the stocks whose asset turnover ratios are most correlated with ALT.

The table below shows ALT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.025 1 -0.839
2021-03-31 0.032 1 -0.867
2020-12-31 0.052 1 -0.992
2020-09-30 0.058 1 -1.332
2020-06-30 0.062 1 -1.567
2020-03-31 0.089 1 -1.191

ALT Price Target

For more insight on analysts targets of ALT, see our ALT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.86 Average Broker Recommendation 1.36 (Strong Buy)

ALT Stock Price Chart Interactive Chart >

Price chart for ALT

ALT Price/Volume Stats

Current price $4.85 52-week high $19.46
Prev. close $5.02 52-week low $3.83
Day low $4.75 Volume 337,700
Day high $5.05 Avg. volume 794,673
50-day MA $5.42 Dividend yield N/A
200-day MA $9.27 Market Cap 209.61M

Altimmune, Inc. (ALT) Company Bio


Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.


ALT Latest News Stream


Event/Time News Detail
Loading, please wait...

ALT Latest Social Stream


Loading social stream, please wait...

View Full ALT Social Stream

Latest ALT News From Around the Web

Below are the latest news stories about Altimmune Inc that investors may wish to consider to help them evaluate ALT as an investment opportunity.

Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Altimmune''s Mid-Stage Pemvidutide Study Cleared By FDA For Obesity

The FDA has cleared Altimmune Inc''s (NASDAQ: ALT ) Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity. Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist under development to treat obesity and nonalcoholic steatohepatitis (NASH). Altimmune expects to initiate the Phase 2 trial in obesity in Q1 of 2022. The Phase 2 clinical trial will enroll approximately Full story available on Benzinga.com

Benzinga | January 31, 2022

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its Phase 2 clinical trial of pemvidutide for obesity. Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist under development for the treatment

Yahoo | January 31, 2022

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | January 28, 2022

It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits.

It's been a bruising start to 2022 on Wall Street — and the tumble moved into correction territory Monday morning with the S&P 500 falling about 10% from a recent high. The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic.

Yahoo | January 24, 2022

Read More 'ALT' Stories Here

ALT Price Returns

1-mo 6.83%
3-mo -30.62%
6-mo N/A
1-year -59.75%
3-year 93.23%
5-year -96.42%
YTD -47.05%
2021 -18.79%
2020 496.83%
2019 -8.25%
2018 -96.55%
2017 -48.19%

Continue Researching ALT

Here are a few links from around the web to help you further your research on Altimmune Inc's stock as an investment opportunity:

Altimmune Inc (ALT) Stock Price | Nasdaq
Altimmune Inc (ALT) Stock Quote, History and News - Yahoo Finance
Altimmune Inc (ALT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8318 seconds.